Hospital outpatient pharmacy leaders cite staffing shortages, managing multiple vendors, and navigating insurer red tape—specialty drug referrals and prior authorization requirements, specifically—among top workplace challenges, a new survey finds. As 340B providers continue to grapple with pharmaceutical manufacturer contract pharmacy restrictions, most respondents said they plan to boost their in-house pharmacy capabilities.
The survey, commissioned by 340B pharmacy management company Maxor 340B and conducted by healthcare consultancy Sage Growth Partners, was released on July 18 and carried out in early 2022. It drew responses from 101 leaders “involved in or serving as influencers in hospital pharmacy decisions/management,” according to the report. Over half (53%) of survey respondents worked in acute care hospitals, 33% in critical access hospitals, and 14% in other facilities.
Hospital outpatient pharmacy leaders cite staffing shortages, managing multiple vendors, and navigating insurer red tape—specialty drug referrals and prior authorization requirements, specifically—among top workplace challenges, a new survey finds. As 340B providers continue to grapple with pharmaceutical manufacturer contract pharmacy restrictions, most respondents said they plan to boost their in-house pharmacy capabilities.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
